HomeNVAX • BMV
add
Novavax Inc
Previous close
$197.00
Day range
$174.50 - $178.07
Year range
$106.50 - $204.88
Market cap
1.65B USD
Avg Volume
103.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 147.14M | 66.61% |
Operating expense | 339.66M | 260.54% |
Net income | 17.53M | 121.63% |
Net profit margin | 11.91 | 112.98% |
Earnings per share | 0.11 | 121.33% |
EBITDA | 13.46M | 111.92% |
Effective tax rate | 2.10% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 735.08M | -20.37% |
Total assets | 1.18B | -24.60% |
Total liabilities | 1.30B | -40.29% |
Total equity | -127.75M | — |
Shares outstanding | 162.94M | — |
Price to book | -249.37 | — |
Return on assets | 1.77% | — |
Return on capital | 19.34% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | 17.53M | 121.63% |
Cash from operations | -39.48M | 77.20% |
Cash from investing | 20.48M | -85.78% |
Cash from financing | -6.60M | -92.99% |
Net change in cash | -27.30M | 36.93% |
Free cash flow | -36.36M | 66.37% |
About
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
Founded
1987
Headquarters
Website
Employees
952
